• Z-DEVD-FMK: Caspase-3 Inhibition in Context

  2026-10-05

  Z-DEVD-FMK is commonly used as a pharmacological probe of caspase-dependent apoptosis, but its reported activity extends beyond caspase-3. This overview examines the compound’s research context, findings from a melanoma-cell preprint, proposed applications in apoptosis assays and neuroprotection research, and the limitations that prevent selective or clinical interpretation.

• Gastrin I (Human): Mechanism and GI Models

  2026-10-05

  Gastrin I is an endogenous peptide hormone that signals through CCK2 receptors to regulate gastric acid secretion. This article distinguishes supplier-reported product attributes from peer-reviewed evidence and explains why hiPSC-derived intestinal organoids support pharmacokinetic research but do not independently validate gastric acid assays.

• (R)-MG132 in Cancer Metabolism Research

  2026-10-04

  A source-grounded overview of (R)-MG132 as a stereoisomeric proteasome control, its relevance to ubiquitin-proteasome system research, and how it may help frame mechanistic interpretation of a 2026 Advanced Science study on HNRNPU K181 lactylation and serine metabolism in cervical cancer.

• CA-074 and Cathepsin B in Necroptosis Research

  2026-10-03

  A source-grounded overview of CA-074, cathepsin B biology, and the evidence linking lysosomal membrane permeabilization to necroptosis, with emphasis on interpretation, applications, and limitations.

• (S)-Mephenytoin for CYP2C19 Pharmacokinetic Studies

  2026-10-02

  Use (S)-Mephenytoin as a defined CYP2C19 substrate to connect enzyme kinetics with human intestinal organoid models. Its measurable 4-hydroxylation pathway supports assay qualification, model comparison, and troubleshooting in translational pharmacokinetic studies.

• Ferroelectric Artificial Photoreceptor for Visual Adaptation

  2026-10-01

  This study introduces a ferroelectric–liquid metal hybrid film that combines azo polymer-grafted liquid metal nanoparticles with a P(VDF-TrFE) matrix to reproduce both low-light and bright-light visual adaptation. In retinal-degeneration models, the implant generated strong visible-to-near-infrared photoelectric responses and improved light sensitivity, while electrophysiological, behavioral, and three-month biocompatibility results support its potential as a broadly responsive retinal prosthesis platform.

• SGC-CBP30: A Causal Assay for LUAD

  2026-10-01

  SGC-CBP30 is a selective CREBBP/EP300 bromodomain inhibitor for dissecting enhancer-dependent transcription in lung adenocarcinoma. This article develops a causal assay framework that connects super-enhancer activity, TGF-β/SMAD3 signaling, and measurable transcriptional outcomes.

• DiscoveryProbe FDA-approved Drug Library for AML

  2026-09-30

  Explore how the DiscoveryProbe FDA-approved Drug Library can support mechanism-first AML research, using the mebendazole–TUBA1A–ZBP1 PANoptosis study to design stronger drug repositioning screening and target-validation workflows.

• DiD for Inflammatory Cell Tracking

  2026-09-30

  DiD (DiDC 18 (5)) provides a red membrane-labeling strategy for resolving macrophage migration, adhesion, and cell-cell interactions in inflammatory models. This article connects probe behavior with the mitochondrial ROS-loop biology of diabetic periodontitis while defining assay boundaries and practical controls.

• Norovirus Co-opts NINJ1 for Selective Secretion

  2026-09-29

  Song and colleagues show that murine norovirus uses the host membrane-rupture factor NINJ1 to release the viral immune-modulatory protein NS1. Combining CRISPR screening, cell biology, mutagenesis, and mouse infection models, the study identifies a caspase-3–NINJ1 pathway that is mechanistically selective but occurs alongside broader damage-associated molecular pattern release.

• Y-27632 Dihydrochloride ROCK Inhibitor Workflows

  2026-09-29

  Y-27632 dihydrochloride gives researchers a practical way to perturb ROCK-dependent cytoskeletal remodeling, cell survival, organoid recovery, and invasion phenotypes. This workflow-focused guide also shows how lessons from a CFTR electrophysiology study can improve timing controls and endpoint selection without confusing ROCK inhibition with CFTR modulation.

• u-Agatoxin IVA: Membrane Structure and Cav2.1 Blockade

  2026-09-28

  The reference study combines NMR spectroscopy, membrane-mimetic micelles, and whole-cell patch clamp to explain how u-Agatoxin IVA interacts with lipid environments and blocks Cav2.1 channels. Its central finding is that the toxin preserves its cystine-knot core while remodeling a previously disordered C-terminal tail, revealing a membrane-dependent mechanism distinct from better-characterized tarantula gating toxins.

• ECL Chemiluminescent Substrate Detection Kit

  2026-09-28

  The ECL Chemiluminescent Substrate Detection Kit (Hypersensitive), SKU K1231, supports HRP-based immunoblotting when target bands are difficult to detect, including low-abundance protein analysis on nitrocellulose or PVDF. It is intended for research immunodetection—not diagnostic use—and its stated sensitivity is not a guaranteed limit of detection for every antibody, sample, or imaging system.

• CA-074 Me: Cathepsin B Inhibitor Workflows

  2026-09-27

  Use CA-074 Me to test whether intracellular cathepsin B contributes to lysosomal damage and cell death—not merely whether a cell-death pathway is active. This practical guide combines dose-finding, lysosomal readouts, orthogonal controls, and selectivity caveats for necroptosis and related studies.

• AST 487 for MPM Research: A Target-First Workflow

  2026-09-26

  A practical guide to evaluating AST 487 in malignant pleural mesothelioma (MPM) research without assuming it inhibits KDM4A. It pairs the reference study’s KDM4A findings with a cautious, reproducible workflow for verifying compound identity, selecting assays, and interpreting results.

8050 records 1/537 page Next 12345 下5页 Last page